Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Derazantinib in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion

Next Previous
Trial Profile

A Phase 1/2 Study of Derazantinib in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Derazantinib (Primary)
  • Indications Cholangiocarcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Basilea Pharmaceutica

Most Recent Events

  • 12 Oct 2020 Results of pooled analysis from two clinical studies and an expanded access program (n=23), presented in a Basilea Pharmaceutica Ltd media release.
  • 12 Oct 2020 According to a Basilea Pharmaceutica Ltd media release, results of pooled analysis from two clinical studies and an expanded access program (n=23) was presented at the Molecular Analysis for Precision Oncology (MAP) Virtual Congress 2020 organized by the European Society for Medical Oncology (ESMO).
  • 30 Sep 2019 According to a Basilea Pharmaceutica media release, results of post hoc analysis were presented at the Annual Congress of the European Society for Medical Oncology (ESMO) 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top